Debut Plus

₹295.6

▼ -6 -1.99%

10 Sept 2026

NSE Listed · Healthcare

ESM · ESM 2
What does ESM · ESM 2 mean?
BSE · Enhanced Surveillance Measure (ESM 2)ESM is the micro/small-cap ramp brake: it fires when a sub-₹1000cr stock's price variation is extreme versus its peer universe, or it's loss-making with a stretched valuation. Practical meaning: intraday speculation is shut off (Trade-for-Trade — every purchase must be taken to delivery), margins go to 100%, and at Stage II price discovery moves to periodic call auctions inside a 2% band.Criteria: Micro / small-cap companies (main-board market-cap below ₹500 cr) shortlisted on objective price parameters — high-low price variation, close-to-close price variation and standard deviation. Stage I = 100% margin + a ≤5% price band + Trade-for-Trade; Stage II = a 2% price band + periodic call auction.Exchange notice · 2026-07-02
NSE · Enhanced Surveillance Measure (ESM 2)ESM is the micro/small-cap ramp brake: it fires when a sub-₹1000cr stock's price variation is extreme versus its peer universe, or it's loss-making with a stretched valuation. Practical meaning: intraday speculation is shut off (Trade-for-Trade — every purchase must be taken to delivery), margins go to 100%, and at Stage II price discovery moves to periodic call auctions inside a 2% band.Criteria: Micro / small-cap companies (main-board market-cap below ₹500 cr) shortlisted on objective price parameters — high-low price variation, close-to-close price variation and standard deviation. Stage I = 100% margin + a ≤5% price band + Trade-for-Trade; Stage II = a 2% price band + periodic call auction.Exchange notice · 2026-07-14

Bafna Pharmaceuticals Ltd. (BAFNAPH)

Volume: 8,827Avg Vol 1W: 5,469Avg Vol 1M: 9,97352W Range:₹94.77₹318.5
NSE BSE www.bafnapharma.com AI Report
Key Ratios
Checked just now
Market Cap₹699 Cr
Current Price₹295.6
Previous Close₹301.6
High / Low (52w)₹318.5 / ₹94.77
Volume8,827
Avg Vol (1W)5,469
Avg Vol (1M)9,973
Stock P/E89.85
Book Value₹40.64
Dividend Yield0%
ROE11.54%
ROA443.8%
Revenue (TTM)₹151 Cr
Revenue Growth-2.65%
Profit Margin5.46%
Total Debt₹3 Cr
Shares Outstanding2 Cr
Face Value₹10
EPS (TTM)₹3.29
P/B7.27
Debt / Equity0.7
50 DMA₹256.66
200 DMA₹166.74
Day change-1.99%
SurveillanceESM · ESM 2
Price Chart
₹295.6▲ 178.26% · 1Y
₹313₹826.7L
2025-09-10
2026-09-10

20-day avg volume: 11K shares

Pros
  • Company is almost debt-free.
Cons
  • Revenue fell 37% YoY.
  • Stock trades at a high P/E of 90.
Quarterly Results
MetricSept 2018Jun 2019Sept 2019Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹9 Cr₹7 Cr₹12 Cr₹39 Cr₹35 Cr₹35 Cr₹38 Cr₹42 Cr
EBITDA₹-1 Cr₹-4 Cr₹-1 Cr₹3 Cr₹4 Cr₹3 Cr₹1 Cr₹2 Cr
Net Profit₹-1 Cr₹-2 Cr₹-1 Cr₹1 Cr₹3 Cr₹3 Cr₹2 Cr₹3 Cr
EPS———0.551.431.320.781.16
Profit & Loss (Annual)
MetricSept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Revenue₹40 Cr₹33 Cr₹39 Cr₹35 Cr₹35 Cr₹38 Cr₹42 Cr₹27 Cr
EBITDA₹3 Cr₹2 Cr₹4 Cr₹4 Cr₹4 Cr₹3 Cr₹4 Cr₹1 Cr
Net Profit₹3 Cr₹1 Cr₹1 Cr₹3 Cr₹3 Cr₹2 Cr₹3 Cr₹0 Cr
EPS————————
Balance Sheet
MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹178 Cr₹138 Cr₹119 Cr₹71 Cr₹130 Cr₹148 Cr₹153 Cr₹176 Cr
Total Liabilities₹136 Cr₹101 Cr₹101 Cr₹20 Cr₹56 Cr₹67 Cr₹68 Cr₹79 Cr
Equity₹42 Cr₹37 Cr₹19 Cr₹51 Cr₹73 Cr₹81 Cr₹85 Cr₹96 Cr
Total Debt————₹23 Cr₹24 Cr₹28 Cr₹37 Cr
Cash Flow
MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹-1 Cr₹-7 Cr₹-2 Cr₹-34 Cr₹5 Cr₹9 Cr₹22 Cr₹15 Cr
Investing₹-5 Cr₹38 Cr₹15 Cr₹33 Cr₹-7 Cr₹-15 Cr₹-21 Cr₹-22 Cr
Financing₹6 Cr₹-31 Cr₹-14 Cr₹7 Cr₹10 Cr₹-84,54,000 Cr₹1 Cr₹6 Cr
Free Cash Flow₹-1 Cr₹-7 Cr₹-2 Cr₹-34 Cr₹-3 Cr₹-6 Cr₹27,62,000 Cr₹-10 Cr
Shareholding
Promoter 75% Institutions 9.34% Public 15.66%
About Bafna Pharmaceuticals Ltd.

Healthcare · Drug Manufacturers - Specialty & Generic

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited is a subsidiary of SRJR Lifesciences LLP.

www.bafnapharma.com ↗
Efficiency & Working Capital
ROCE10.6%
Interest Coverage-17.8
Dividend Payout—
Debtor Days52 d
Inventory Days98 d
Payable Days108 d
Cash Conversion Cycle42 d
Working Capital Days150 d
Shareholding Details

As of 2026-06-30

Promoter75%
FII9.3%
DII0%
Institutions9.3%
Public15.7%
Promoter Pledge0%
No. of Shareholders7,062
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters88.7%88.4%88.3%88.3%88.3%88.3%75%75%75%75%75%75%
FIIs0%0%0%0%0%0%8.5%9.3%9.3%9.3%9.3%9.3%
DIIs0%0%0%0%0%0%0%0%0%0%0%0%
Public11.3%11.6%11.7%11.7%11.7%11.7%16.5%15.7%15.7%15.7%15.7%15.7%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders7,3547,3677,5397,3917,2957,2147,1427,2837,5727,1196,9287,062
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202603————
Major Shareholders (>1%)
NameCategoryStakeShares
Srjr Lifesciences LlpShareholding of Promoter and Promoter Group74.6%1.76 Cr
M7 Global Fund Pcc-aerionPublic Shareholding3.2%7,60,059
M7 Global Fund Pcc - Cell Dewcap FundPublic Shareholding3.1%7,37,158
Zeal Global Opportunities FundPublic Shareholding3%7,12,586
Alpana MundraPublic Shareholding2.7%6,46,350
Monarch Networth Finserve Private LimitedPublic Shareholding1.4%3,18,254
Guttikonda Vara LakshmiPublic Shareholding1.3%3,04,223
P Paras BafnaShareholding of Promoter and Promoter Group0.2%50,000
Navin BafnaShareholding of Promoter and Promoter Group0.2%42,015
Mahaveer Chand BafnaShareholding of Promoter and Promoter Group0%6,338
Sasikala BafnaShareholding of Promoter and Promoter Group0%1,844
Amri Bai BafnaShareholding of Promoter and Promoter Group0%1,989
Paras BafnaShareholding of Promoter and Promoter Group0%49
Chetna BafnaShareholding of Promoter and Promoter Group0%0
Mahaveer Chand Bafna HufShareholding of Promoter and Promoter Group0%0
Board of Directors
NameDesignationYear
Ravichandran ChitraChairperson2026
Shanmugam HemalathaE D & Wholetime Director2026
Vinayak Dinesh DendukuriED / WTD - Quality2026
Akilapriya Chandrashekar RajuNon-Exec & Non-Independent Dir2026
Upendar Mekala ReddyNon-Exec & Non-Independent Dir2026
A MohanachandranCompany Sec. & Compli. Officer2026
Palamadai Krishnan SundaresanIndependent Director2026
Segments — Product
SegmentRevenueShare
Manufacturing and trading of pharma₹0 Cr—
Segments — Geography
RegionRevenueShare
INDIA₹41 Cr63.8%
ASIA₹14 Cr21.8%
AFRICA₹1 Cr2.3%
UK₹8 Cr12.1%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2026₹10402424
Corporate Actions
TypeDateValueRemark
forthcoming2026-08-11Board Meetings—
forthcoming—Book ClosureAnnual General Meeting
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
2026000214
2026000203
2026000011
Insider / Designated-Person Trades

25 recent disclosure(s)

SRJR LIFESCIENCES LLPDisposal · 3,14,530
SRJR LIFESCIENCES LLPDisposal · 28,30,766
SRJR LIFESCIENCES LLPDisposal · 41,919
SRJR LIFESCIENCES LLP RevisedDisposal · 30,000
SRJR LIFESCIENCES LLPDisposal · 23,401
SRJR LIFESCIENCES LLPDisposal · 30,000
Substantial Acquisitions (SAST)

1 disclosure(s)

Offer For Sale07/09/2023 - 08/09/2023 · 2,98,666
Company Information
Incorporated1995
ChairmanRavichandran Chitra
AuditorBrahmayya & Co
Investor Email[email protected]; [email protected]
🌐 www.bafnapharma.com ↗

📍 Bafna Towers New No 68, Old No 299 Thambu Chetty St, Chennai, Tamil Nadu, 600001

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

AYM Syntex LimitedAzad Engineering LimitedAzad India Mobility Ltd.Baba Arts Ltd.Baba Arts LtdBaba Food Processing India Ltd.B.A.G.Convergence LimitedBAG Films And Media Ltd.Bagmane Prime Office REITBaheti Recycling Industries Ltd.Baid Finserv LimitedBajaj AutoAll “B” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search